33 Recent analysis shows that regarding PFS, time to treatment failure, ORR, and duration of response, there is a slight trend in favor of afatinib. 34 , 35 These results will be very important for the registration strategy for afatinib and for the selection criteria of optimal EGFR TKI as the first-line treatment for cancers with EGFR mutation. 24 Afatinib and SCC In LUX-Lung 5, among the 1,154 enrolled patients, 90 (7.8%) had SCC histology and received afatinib in part A of the trial.
← all excerpts
Spotlight on afatinib and its potential in the treatment of squamous cell lung cancer: the evidence so far.
1
—
—